J. Sipil a¨ et al. / European Journal of Pharmaceutical Sciences 25 (2005) 417–425
425
Congy, C., Labeeuw, B., Gueule, P., Rinaldi, M., 1990. Preparation of
chalcone oxime ethers as 5-HT2 receptor antagonists and platelet an-
tiaggregants, EP 373998.
Lotta, T., Taskinen, J., B a¨ ckstr o¨ m, R., Nissinen, E., 1992. Pls model-
ing of structure–activity-relationships of catechol O-methyltransferase
inhibitors. J. Comput. Aid. Mol. Des. 6 (3), 253–272.
Ermondi, G., Lorenti, M., Caron, G., 2004. Contribution of ionization and
lipophilicity to drug binding to albumin: a preliminary step toward
biodistribution prediction. J. Med. Chem. 47 (16), 3949–3961.
Ertel, W., Friedrich, K., 1977. Umsetzung von Aromaten mit
Chlormethylenmalons a¨ ure-Derivaten. Eine neue Synthese aromatis-
cher Aldehyde. Chem. Ber. 110, 86–95.
Flynn, D.L., Belliotti, T.R., Boctor, A.M., Connor, D.T., Kostlan, C.R.,
Nies, D.E., Ortwine, D.F., Schrier, D.J., Sircar, J.C., 1991. Styrylpyra-
zoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase
and cyclooxygenase inhibitors. J. Med. Chem. 34 (2), 518–525.
H a¨ nninen, K., Kaukonen, A.M., Kankkunen, T., Hirvonen, J., 2003. Rate
and extent of ion-exchange process: the effect of physico-chemical
characteristics of salicylate anions. J. Contr. Release 91 (3), 449–463.
Higa, T., Sakai, R., 1988. Antiviral guanidine derivative compositions and
their methods of use, WO 8800181 EP 271571.
Lyall, R.M., Zilberstein, A., Gazit, A., Gilon, C., Levitzki, A., Sch-
lessinger, J., 1989. Tyrphostins inhibit epidermal growth factor (EGF)-
receptor tyrosine kinase activity in living cells and EGF-stimulated
cell proliferation. J. Biol. Chem. 264 (24), 14503–14509.
Maurin, B., Grant, J.W., Stahl, P.H., 2002. In: Stahl, P.H., Wermuth, C.G.
(Eds.), Handbook of Pharmaceutical Salts—Properties, Selection, Use.
Verlag Helvetica Chimica Acta, Z u¨ rich, pp. 9–17.
Nishioka, T., Watanabe, J., Kawabata, J., Niki, R., 1997. Isolation
and activity of N-p-coumaroyltyramine, an ␣-glucosidase inhibitor in
Welsh onion (Allium fistulosum). Biosci. Biotechnol. Biochem. 61 (7),
1138–1141.
Rinaldi-Carmona, M., Congy, C., Santucci, V., Simiand, J., Gautret, B.,
Neliat, G., Labeeuw, B., Le Fur, G., Soubrie, P., Breliere, J.C., 1992.
Biochemical and pharmacological properties of SR 46349B, a new po-
tent and selective 5-hydroxytryptamine2 receptor antagonist. J. Phar-
macol. Exp. Ther. 262 (2), 759–768.
Hilal, S.H., Carreira, L.A., Karickhoff, S.W., 1994. Sparc—a computer-
program for estimation of physicochemical properties. Abstr. Pap. Am.
Chem. Soc. 208, 189-COMP Part 1.
¨
Rosenmund, K.W., 1913. Uber Phenyl- a¨ thanol-amine und Phenyl-nitro-
a¨ thanole und ihre Oxy Derivative. Ber. Deutsch. Chem. Ges. 46,
1034–1050.
Schiefer, S., Kindl, H., 1971. 14C-Synthesen biologisch interessanter p-
substituierter Aryl a¨ than-K o¨ rper. J. Labelled Compd. Radiopharm. 7
(3), 291–297.
Hori, K., Nakamura, K., Kawai, M., Mogi, I., Imokawa, G., Takaishi, N.,
1
987. Preparation of N,N-dialkyl-p-hydroxycinnamamides as melanin
inhibitors, JP 62056459.
Hori, K., Nakamura, K., Kawai, M., Motegi, I., Imokawa, G., Takaishi, N.,
1
988. Preparation of (2-hydroxyethyl)cinnamamides and skin lighten-
Shedlovsky, T. (Ed.), 1962. The Behaviour of Carboxylic Acids in Mixed
Solvents. Pergamon Press, Oxford.
ers containing them, EP 255695.
Isshiki, K., Imoto, M., Sawa, T., Umezawa, K., Takeuchi, T., Umezawa,
H., Tsuchida, T., Yoshioka, T., Tatsuta, K., 1987. Inhibition of tyro-
sine protein kinase by synthetic erbstatin analogs. J. Antibiot. 40 (8),
Still, W.C., Kahn, M., Mitra, K., 1978. Rapid chromatographic technique
for preparative separations with moderate resolution. J. Org. Chem.
43, 2923–2925.
1
209–1210.
Jaffe, H.H., 1953. A reexamination of the Hammett equation. Chem. Rev.
3 (2), 191–261.
Tak a´ cs-Nov a´ k, K., Box, K.J., Avdeef, A., 1997. Potentiometric pKa
determination of water-insoluble compounds: validation study in
methanol/water mixtures. Int. J. Pharm. 151 (2), 235–248.
Taskinen, J., Vidgren, J., Ovaska, M., B a¨ ckstr o¨ m, R., Pippuri,
A., Nissinen, E., 1989. Qsar and binding model for inhibi-
tion of rat-liver catechol-O-methyl-transferase by 1,5-substituted-3,4-
dihydroxybenzenes. Quant. Struct. Act. Rel. 8 (3), 210–213.
van de Waterbeemd, H., Gifford, E., 2003. ADMET in silico modelling:
towards prediction paradise? Nat. Rev. Drug Discov. 2 (3), 192–204.
Wikberg, T., Ottoila, P., Taskinen, J., 1993. Identification of major urinary
metabolites of the catechol-O-methyltransferase inhibitor entacapone
in the dog. Eur. J. Drug Metabol. Pharmacokinet. 18 (4), 359–367.
Williams, A., 1984. In: Page, M.I. (Ed.), The Chemistry of Enzyme
Action, vol. 6. Elsevier Science Publishers B.V., Amsterdam, pp.
127–202.
5
Kaakkola, S., Gordin, A., M a¨ nnist o¨ , P.T., 1994. General-properties
and clinical possibilities of new selective inhibitors of catechol O-
methyltransferase. Gen. Pharmacol. 25 (5), 813–824.
Kad, G.L., Singh, V., Khurana, A., Singh, J., 1998. The synthesis of
physocopsisenone, a new secondary metabolite from the sponge phy-
copsis sp. J. Nat. Prod. 61 (2), 297–298.
Kaupp, G., Reza Naimi-Jamal, M., Schmeyers, J., 2003. Solvent-free Kno-
evenagel condensations and Michael additions in the solid state and
in the melt with quantitative yield. Tetrahedron 59 (21), 3753–3760.
Kennedy, T., 1997. Managing the drug discovery/development interface.
Drug Discov. Today 2 (10), 436–444.
Lautala, P., Ulmanen, I., Taskinen, J., 2001. Molecular mechanisms con-
trolling the rate and specificity of catechol O-methylation by human
soluble catechol O-methyltransferase 59 (2), 393–402.
Williams, A., 2003. Free Energy Relationships in Organic and Bio-organic
Chemistry. The Royal Society of Chemistry, Cambridge.
Yasuda, M., 1959. Dissociation constants of some carboxylic acids in
mixed aqueous solvents. Bull. Chem. Soc. Jpn. 32 (5), 429–432.
Livingstone, D.J., 2003. Theoretical property predictions. Curr. Top. Med.
Chem. 3 (10), 1171–1192.